Literature DB >> 22264702

Novel mutation of GLRA1 in Omani families with hyperekplexia and mild mental retardation.

Amna Mohammed Al-Futaisi1, Mohammed Nasser Al-Kindi, Al-Mundher Al-Mawali, Roshan Lal Koul, Samir Al-Adawi, Said Ali Al-Yahyaee.   

Abstract

Hyperekplexia is characterized by neonatal hypertonia and exaggerated startle reflex in response to loud noise or tactile stimuli. Mutations in patients with hyperekplexia were evident in several genes encoding proteins involved in glycinergic neurotransmission, i.e., glycine receptor α and β subunits, collybistin, gephyrin, and glycine transporter 2. We clinically and genetically characterized two large, unrelated consanguineous families with hyperekplexia. Affected members of the two families manifested hyperekplexia with mild mental retardation. Patients exhibited a novel homozygote c.593G>C missense mutation in GLRA1, resulting in amino acid substitution p.W170S in the corresponding mature glycine receptor α1 subunit. This mutation was absent in 400 randomly selected chromosomes in the same population. In conclusion, a novel p.W170S mutation in the extracellular ligand binding domain of glycine receptor α1 subunit was detected in patients with hyperekplexia and mild mental retardation. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264702     DOI: 10.1016/j.pediatrneurol.2011.11.008

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  11 in total

1.  Emerging Burden of Frail Young and Elderly Persons in Oman: For whom the bell tolls?

Authors:  Hamed Al-Sinawi; Mohammed Al-Alawi; Rehab Al-Lawati; Ahmed Al-Harrasi; Mohammed Al-Shafaee; Samir Al-Adawi
Journal:  Sultan Qaboos Univ Med J       Date:  2012-04-09

2.  The GLRA1 missense mutation W170S associates lack of Zn2+ potentiation with human hyperekplexia.

Authors:  Ning Zhou; Chen-Hung Wang; Shu Zhang; Dong Chuan Wu
Journal:  J Neurosci       Date:  2013-11-06       Impact factor: 6.167

3.  Investigating the Mechanism by Which Gain-of-function Mutations to the α1 Glycine Receptor Cause Hyperekplexia.

Authors:  Yan Zhang; Anna Bode; Bindi Nguyen; Angelo Keramidas; Joseph W Lynch
Journal:  J Biol Chem       Date:  2016-05-18       Impact factor: 5.157

Review 4.  Glycine receptor mouse mutants: model systems for human hyperekplexia.

Authors:  Natascha Schaefer; Georg Langlhofer; Christoph J Kluck; Carmen Villmann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 5.  The impact of human hyperekplexia mutations on glycine receptor structure and function.

Authors:  Anna Bode; Joseph W Lynch
Journal:  Mol Brain       Date:  2014-01-09       Impact factor: 4.041

6.  A de novo CTNNB1 nonsense mutation associated with syndromic atypical hyperekplexia, microcephaly and intellectual disability: a case report.

Authors:  Anna Winczewska-Wiktor; Magdalena Badura-Stronka; Anna Monies-Nowicka; Michal Maciej Nowicki; Barbara Steinborn; Anna Latos-Bieleńska; Dorota Monies
Journal:  BMC Neurol       Date:  2016-03-12       Impact factor: 2.474

7.  The Free Zinc Concentration in the Synaptic Cleft of Artificial Glycinergic Synapses Rises to At least 1 μM.

Authors:  Yan Zhang; Angelo Keramidas; Joseph W Lynch
Journal:  Front Mol Neurosci       Date:  2016-09-22       Impact factor: 5.639

8.  The GlyR Extracellular β8-β9 Loop - A Functional Determinant of Agonist Potency.

Authors:  Dieter Janzen; Natascha Schaefer; Carolyn Delto; Hermann Schindelin; Carmen Villmann
Journal:  Front Mol Neurosci       Date:  2017-10-09       Impact factor: 5.639

9.  A microdeletion at Xq22.2 implicates a glycine receptor GLRA4 involved in intellectual disability, behavioral problems and craniofacial anomalies.

Authors:  Jonathan D J Labonne; Tyler D Graves; Yiping Shen; Julie R Jones; Il-Keun Kong; Lawrence C Layman; Hyung-Goo Kim
Journal:  BMC Neurol       Date:  2016-08-09       Impact factor: 2.474

Review 10.  Impaired Glycine Receptor Trafficking in Neurological Diseases.

Authors:  Natascha Schaefer; Vera Roemer; Dieter Janzen; Carmen Villmann
Journal:  Front Mol Neurosci       Date:  2018-08-21       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.